Personalis, Inc. (PSNL): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSNL POWR Grades
- Value is the dimension where PSNL ranks best; there it ranks ahead of 70.44% of US stocks.
- PSNL's strongest trending metric is Momentum; it's been moving down over the last 177 days.
- PSNL's current lowest rank is in the Growth metric (where it is better than 5.04% of US stocks).
PSNL Stock Summary
- With a year-over-year growth in debt of 508.55%, PERSONALIS INC's debt growth rate surpasses 96.25% of about US stocks.
- Revenue growth over the past 12 months for PERSONALIS INC comes in at -7.43%, a number that bests only 14.83% of the US stocks we're tracking.
- In terms of volatility of its share price, PSNL is more volatile than 94.45% of stocks we're observing.
- Stocks that are quantitatively similar to PSNL, based on their financial statements, market capitalization, and price volatility, are ATOM, EYEN, SDGR, BGRY, and DYAI.
- PSNL's SEC filings can be seen here. And to visit PERSONALIS INC's official web site, go to www.personalis.com.
PSNL Valuation Summary
- In comparison to the median Healthcare stock, PSNL's price/sales ratio is 59.14% lower, now standing at 1.9.
- PSNL's price/earnings ratio has moved up 38.7 over the prior 40 months.
Below are key valuation metrics over time for PSNL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PSNL | 2022-09-23 | 1.9 | 0.5 | -1.5 | -1.1 |
| PSNL | 2022-09-22 | 1.9 | 0.5 | -1.5 | -1.1 |
| PSNL | 2022-09-21 | 1.9 | 0.6 | -1.6 | -1.2 |
| PSNL | 2022-09-20 | 2.0 | 0.6 | -1.6 | -1.2 |
| PSNL | 2022-09-19 | 2.2 | 0.6 | -1.8 | -1.4 |
| PSNL | 2022-09-16 | 2.1 | 0.6 | -1.7 | -1.4 |
PSNL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PSNL has a Quality Grade of D, ranking ahead of 6.55% of graded US stocks.
- PSNL's asset turnover comes in at 0.259 -- ranking 67th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows PSNL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.259 | 0.327 | -0.268 |
| 2021-03-31 | 0.311 | 0.292 | -0.325 |
| 2020-12-31 | 0.398 | 0.256 | -0.443 |
| 2020-09-30 | 0.436 | 0.269 | -0.492 |
| 2020-06-30 | 0.482 | 0.283 | -0.583 |
| 2020-03-31 | 0.426 | 0.315 | -0.904 |
PSNL Price Target
For more insight on analysts targets of PSNL, see our PSNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $33.57 | Average Broker Recommendation | 1.38 (Strong Buy) |
PSNL Stock Price Chart Interactive Chart >
PSNL Price/Volume Stats
| Current price | $3.36 | 52-week high | $21.69 |
| Prev. close | $2.97 | 52-week low | $2.84 |
| Day low | $3.05 | Volume | 581,200 |
| Day high | $3.49 | Avg. volume | 517,635 |
| 50-day MA | $3.76 | Dividend yield | N/A |
| 200-day MA | $6.80 | Market Cap | 154.28M |
Personalis, Inc. (PSNL) Company Bio
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Latest PSNL News From Around the Web
Below are the latest news stories about PERSONALIS INC that investors may wish to consider to help them evaluate PSNL as an investment opportunity.
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceMENLO PARK, Calif., August 30, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. |
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight DiagnosticsMENLO PARK, Calif., August 17, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detection of molecular residual disease (MRD). |
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MENLO PARK, Calif., August 16, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan. |
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic CancersMENLO PARK, Calif. & VANCOUVER, British Columbia, August 15, 2022--Personalis in partnership with BC Cancer to assess clinical and economic benefits of ctDNA for colorectal and pancreatic cancers |
Is Personalis (NASDAQ:PSNL) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
PSNL Price Returns
| 1-mo | 5.00% |
| 3-mo | -9.19% |
| 6-mo | -58.16% |
| 1-year | -80.67% |
| 3-year | -73.56% |
| 5-year | N/A |
| YTD | -76.45% |
| 2021 | -61.02% |
| 2020 | 235.87% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...